secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-109295
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics appoints Michael Nofi as CFO, succeeding retiring CFO Carruthers
--------------------------------------------------------------------------------

- Michael Nofi appointed CFO effective Nov 10, 2025; replaces R. Michael Carruthers who retired.
- Nofi's annual base salary: $465,000, target cash bonus 40% of salary, plus stock option for 262,500 shares and 43,750 RSUs.
- Carruthers to remain employee until Jan 31, 2026, then consultant through Oct 31, 2026, with continued equity vesting.
- Nofi previously Chief Accounting Officer at SpringWorks Therapeutics; brings 30+ years life sciences finance experience.
- No disagreement between Carruthers and company; transition supports Edgewise's late-stage clinical and commercialization prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925109295/0001104659-25-109295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925109295/tm2530663d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer